Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of our group over the years.
|2017||Paris (France), 9 January 2017 – Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is a clinically differentiated and FDA-approved product for patients with high unmet medical needs.|
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including COMETRIQ®, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). The companies have agreed to collaborate on the development of cabozantinib for current and potential future indications. Exelixis will maintain exclusive commercial rights for cabozantinib in the United States and Canada, and continue its discussions to partner commercial rights in Japan.
Ipsen and Active Biotech present encouraging results from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer and initiate a new phase II, proof-of-concept clinical trial to evaluate the safety and efficacy of tasquinimod in other cancer indications.
Somatuline® receives marketing authorization in Japan for the treatment of acromegaly and pituitary gigantism and becomes Ipsen’s first drug available worldwide.
Inspiration Biopharmaceuticals, Inc., Ipsen’s partner, initiates a voluntary reorganization plan of its activities under the Chapter 11 of US Bankruptcy Code.
Ipsen announces a new growth strategy based on three pillars:
Ipsen and the Salk Institute renew the “Ipsen Life Sciences Program” for a further three years.
Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics.
Ipsen strengthens its business in urology-oncology with the acquisition of the rights to Heavy® (a drug aimed at improving bladder cancer detection) and the establishment of two significant partnerships with: Active Biotech for the co-development and commercialization of tasquinimod (a molecule for the treatment of metastatic and castration-resistant prostate cancers), and Institut Gustave Roussy in the area of medical oncology to leverage the combined expertise of their respective R&D teams.
|2009||Ipsen and Galderma receive collective green light for Azzalure® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines.
Azzalure® receives marketing authorization in the UK, France and Germany. The FDA approves Dysport™ for therapeutic and aesthetic use.
The European Medicines Agency (EMA) delivers marketing authorization for the 6-month formulation of Decapeptyl® in nine European countries. The product is launched in France
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
Ipsen reinforces its presence in the US with three acquisitions: Tercica Inc. in endocrinology, Apokyn® in neurology and Vernalis’ US commercial operations, and all assets related to OBI-1 from Octagen in hematology.
|2005||Ipsen’s shares are listed on Euronext Paris. Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.|
|The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).||2004|
|2003||Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe.|
|Ipsen launches Somatuline®Autogel® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, Somatuline® Autogel® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.||2001-2002|
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe
|Ipsen launches Forlax®, a product used for the treatment of constipation.||1996|
|1995||The Group launches Somatuline®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.|
|1992||Ipsen begins its development in China, with the opening of a representative office in Tianjin.|
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
|1980||Ipsen initiates a partnership with Debiopharm. This collaboration leads to the marketing of Decapeptyl® in 1986. This analogue of natural GnRH hormone (or gonadotropin) is indicated for the treatment of prostate cancer, endometriosis and infertility. Decapeptyl® has been a key driver of the Group’s international expansion.|
|The Group enters an expansion phase with the launch of Ginkor®, Tanakan® and Smecta®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).||1970|
|1969||The Group opens its first research facility in Les Ulis (France).|
The Group launches Citrate de Betaïne®, a product used in the symptomatic treatment of dyspepsia.
|1929||Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch Romarène®, a product derived from rosemary for the treatment of digestive disorders.|